Tumor Infiltrating Lymphocytes
**Note:** The following describes an area of investigational scientific research. BH Onco's cellular products are investigational, have not been approved by the U.S. FDA, and are not offered as a treatment for any disease.
Tumor Infiltrating Lymphocytes (TILs) represent a promising approach in cancer immunotherapy by utilizing the body's own immune cells to target and destroy tumor cells. TILs are a diverse population of immune cells that naturally migrate into tumors, where they can recognize and attack cancer cells. The process involves isolating these lymphocytes from a patient's tumor tissue, expanding them in the laboratory to increase their numbers, and then re-infusing them back into the patient. This expanded population of TILs is specifically trained to target cancer cells that share the same antigens, potentially leading to a robust and focused immune attack against the tumor. TIL therapy has shown significant promise, particularly in treating solid tumors like melanoma, where it has achieved notable clinical successes. By harnessing the natural immune response of these cells and enhancing their anti-tumor capabilities, TIL therapy offers a highly personalized and potentially powerful strategy to improve outcomes for patients with difficult-to-treat cancers.
Date:
November 29, 2022
Category:
